DR. WILL ROWLAND VOELZKE M.D. NPI 1023205697

NPI Details

DR. Will Rowland Voelzke, M.D. is a hematology and oncology internal medicine in Richmond, VA with 23 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Will Rowland Voelzke, M.D. NPI is 1023205697. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: BAYLOR COLLEGE OF MEDICINE
Graduation Year:2002

The provider's business location address is:

1401 JOHNSTON WILLIS DR
SUITE 100
RICHMOND, VA
ZIP 23235-730
Phone: (804) 330-7990
Fax: (804) 330-2701

The NPI 1023205697 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS:Q0138)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, epoetin alfa, (for non-esrd use), 1000 units (HCPCS:J0885)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, bortezomib, not otherwise specified, 0.1 mg (HCPCS:J9044)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, granisetron hydrochloride, 100 mcg (HCPCS:J1626)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Injection, pegfilgrastim-bmez, biosimilar, (ziextenzo), 0.5 mg (HCPCS:Q5120)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Follow-up hospital inpatient care per day, typically 25 minutes (HCPCS:99232)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Drawing of blood for a medical problem (HCPCS:99195)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Injection of drug or substance into vein (HCPCS:96374)
• Initial hospital inpatient care per day, typically 50 minutes (HCPCS:99222)
• Administration of chemotherapy into vein using push technique (HCPCS:96409)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)

The enumeration date for this NPI number is 9/27/2007 and was last updated on 5/24/2021.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available:

Other Identifiers

The following information regarding additional identifiers associated to this NPI record includes the other identifier number, identifier type, identifier state and issuer.